ONE Mylan refers to our goal of providing every single one of our customers around the world with the products they need to serve the patients who depend on them.
To help us achieve this goal, we’ve built a portfolio of more than 7,500 products that includes brand-name medicines, branded generics, generics and over-the-counter remedies across 10 therapeutic franchises. As important, Mylan continues to invest in the future. Our pipeline includes nearly 8,000 products whose applications are either currently under review by health authorities or whose submissions are planned.
We’ve made supply-chain reliability a top priority – we know it’s vital for customers to have products in stock whenever and wherever they’re needed to serve patients. In 2016, that meant getting approximately 68 billion doses of our high quality medicines safely to their proper destinations on time.
We collaborate with customers to develop services that help patients better understand and treat their medical conditions. Our Ashray disease-awareness program in India is a great example. It provides patients who have Hepatitis C or breast cancer – and their families – with emotional and psychological support provided by trained multi-lingual counselors.
Another example of innovation was our introduction of MyTest kits in France this year. Individuals use them at home to detect conditions such as urinary tract infections, tetanus, ulcers and iron deficiency. Available in pharmacies, the kits are intended to prompt conversations between patients and pharmacists, who can, if appropriate, provide referrals.
We believe that access to healthcare should be a right, not a privilege, which is why patients are at the heart of everything we do. Moreover, patients in developing countries all too often face higher hurdles in accessing the care they need, so we’ve made serving these markets a priority.
- We have, for instance, as of the first quarter of this year, approvals for our Trastuzumab biosimilar in 15 developing markets. The product treats breast cancer.
- Mylan is – by far – the world’s largest producer by volume of antiretroviral (ARV) drugs, which treat HIV/AIDS. Nearly half of the approximately 16.5 million people currently on antiretroviral therapy, or ART, in developing countries use a Mylan ARV every day.
Nonadherence to prescriptions is a problem everywhere. Up to 30% of prescriptions in the U.S., for instance, are never filled.* And even when they are, patients may miss doses, take the wrong dose, stop treatment early or never start. The cost to the nation: approximately one dollar out of every nine spent on healthcare.
Mylan offers a wide variety of products and services to help address this issue. Our MyFreshStart™ program in Europe and Australia, for instance, educates patients about a variety of medical conditions and explains ways to better manage them by engaging in activities like quizzes, dashboards and sweepstakes. We provide MyFreshStart to physicians, through which most patients enroll. Everyone wins – the patients, the physicians, the healthcare system and other Mylan stakeholders.
* Express Scripts. The Costs of Nonadherence, 2015
Read more about Global Social Responsibility at Mylan